Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ)
CNY 7.43
(-9.06%)
CNY 7.43
(-9.06%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.36 Million CNY | -24.39% |
| 2022 | 5.77 Million CNY | -81.44% |
| 2021 | 31.1 Million CNY | 54.26% |
| 2020 | 20.16 Million CNY | -79.17% |
| 2019 | 96.78 Million CNY | 409.37% |
| 2018 | 19 Million CNY | -52.5% |
| 2017 | 40 Million CNY | 101.01% |
| 2016 | 19.9 Million CNY | -33.89% |
| 2015 | 30.1 Million CNY | -11.47% |
| 2014 | 34 Million CNY | 126.67% |
| 2013 | 15 Million CNY | -19.14% |
| 2012 | 18.55 Million CNY | -17.56% |
| 2011 | 22.5 Million CNY | 0.0% |
| 2010 | 22.5 Million CNY | 0.0% |
| 2009 | - CNY | 0.0% |
| 2008 | - CNY | -100.0% |
| 2007 | 22 Million CNY | 0.0% |
| 2006 | 22 Million CNY | 193.33% |
| 2005 | 7.5 Million CNY | 0.0% |
| 2004 | - CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.99 Million CNY | 0.0% |
| 2024 Q1 | - CNY | -100.0% |
| 2024 Q3 | - CNY | 327.02% |
| 2023 FY | 4.36 Million CNY | -24.39% |
| 2023 Q4 | 4.36 Million CNY | 0.0% |
| 2023 Q1 | - CNY | -100.0% |
| 2023 Q2 | 5.87 Million CNY | 0.0% |
| 2023 Q3 | - CNY | -100.0% |
| 2022 Q2 | 4.9 Million CNY | -76.71% |
| 2022 Q1 | 21.05 Million CNY | -32.3% |
| 2022 Q3 | - CNY | -100.0% |
| 2022 Q4 | 5.77 Million CNY | 0.0% |
| 2022 FY | 5.77 Million CNY | -81.44% |
| 2021 Q4 | 31.1 Million CNY | 0.0% |
| 2021 Q3 | 31.1 Million CNY | 0.0% |
| 2021 Q2 | 31.1 Million CNY | 105.28% |
| 2021 Q1 | 15.15 Million CNY | -24.85% |
| 2021 FY | 31.1 Million CNY | 54.26% |
| 2020 Q4 | 20.16 Million CNY | -73.11% |
| 2020 FY | 20.16 Million CNY | -79.17% |
| 2020 Q1 | 90 Million CNY | -7.01% |
| 2020 Q2 | 75 Million CNY | -16.67% |
| 2020 Q3 | 75 Million CNY | 0.0% |
| 2019 Q1 | 19 Million CNY | 0.0% |
| 2019 FY | 96.78 Million CNY | 409.37% |
| 2019 Q3 | 84 Million CNY | 0.0% |
| 2019 Q4 | 96.78 Million CNY | 15.22% |
| 2019 Q2 | 84 Million CNY | 342.11% |
| 2018 Q3 | 20 Million CNY | -33.33% |
| 2018 Q1 | 22 Million CNY | -45.0% |
| 2018 FY | 19 Million CNY | -52.5% |
| 2018 Q2 | 30 Million CNY | 36.36% |
| 2018 Q4 | 19 Million CNY | -5.0% |
| 2017 Q3 | 30 Million CNY | 0.0% |
| 2017 Q2 | 30 Million CNY | 50.0% |
| 2017 Q1 | 20 Million CNY | 0.5% |
| 2017 Q4 | 40 Million CNY | 33.33% |
| 2017 FY | 40 Million CNY | 101.01% |
| 2016 Q3 | 33.5 Million CNY | 42.55% |
| 2016 Q4 | 19.9 Million CNY | -40.6% |
| 2016 Q1 | 23.5 Million CNY | -21.93% |
| 2016 FY | 19.9 Million CNY | -33.89% |
| 2016 Q2 | 23.5 Million CNY | 0.0% |
| 2015 Q2 | 35.7 Million CNY | 24.39% |
| 2015 FY | 30.1 Million CNY | -11.47% |
| 2015 Q4 | 30.1 Million CNY | 18.97% |
| 2015 Q3 | 25.3 Million CNY | -29.13% |
| 2015 Q1 | 28.7 Million CNY | -15.59% |
| 2014 Q2 | 24.3 Million CNY | 0.0% |
| 2014 Q3 | 29.2 Million CNY | 20.16% |
| 2014 Q4 | 34 Million CNY | 16.44% |
| 2014 Q1 | 24.3 Million CNY | 62.0% |
| 2014 FY | 34 Million CNY | 126.67% |
| 2013 Q3 | 15 Million CNY | 0.0% |
| 2013 Q4 | 15 Million CNY | 0.0% |
| 2013 Q1 | 13.05 Million CNY | -29.65% |
| 2013 FY | 15 Million CNY | -19.14% |
| 2013 Q2 | - CNY | -100.0% |
| 2012 Q3 | 18.55 Million CNY | 7.23% |
| 2012 FY | 18.55 Million CNY | -17.56% |
| 2012 Q4 | 18.55 Million CNY | 0.0% |
| 2012 Q2 | 17.3 Million CNY | -38.21% |
| 2012 Q1 | 28 Million CNY | 24.44% |
| 2011 Q3 | 30 Million CNY | 0.0% |
| 2011 FY | 22.5 Million CNY | 0.0% |
| 2011 Q4 | 22.5 Million CNY | -25.0% |
| 2011 Q1 | 22.5 Million CNY | 0.0% |
| 2011 Q2 | 30 Million CNY | 33.33% |
| 2010 Q1 | - CNY | 0.0% |
| 2010 Q4 | 22.5 Million CNY | -25.0% |
| 2010 Q3 | 30 Million CNY | 0.0% |
| 2010 Q2 | 30 Million CNY | 0.0% |
| 2010 FY | 22.5 Million CNY | 0.0% |
| 2009 Q4 | - CNY | 0.0% |
| 2009 Q3 | - CNY | 0.0% |
| 2009 Q2 | - CNY | 0.0% |
| 2009 Q1 | - CNY | 0.0% |
| 2009 FY | - CNY | 0.0% |
| 2008 FY | - CNY | -100.0% |
| 2008 Q1 | 10 Million CNY | -54.55% |
| 2008 Q2 | - CNY | -100.0% |
| 2008 Q3 | - CNY | 0.0% |
| 2008 Q4 | - CNY | 0.0% |
| 2007 Q4 | 22 Million CNY | 0.0% |
| 2007 Q2 | 22 Million CNY | 0.0% |
| 2007 FY | 22 Million CNY | 0.0% |
| 2007 Q3 | 22 Million CNY | 0.0% |
| 2006 FY | 22 Million CNY | 193.33% |
| 2006 Q4 | 22 Million CNY | 0.0% |
| 2005 FY | 7.5 Million CNY | 0.0% |
| 2004 FY | - CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 2.54 Billion CNY | 99.828% |
| Zhejiang Zhenyuan Share Co., Ltd. | 138.12 Million CNY | 96.839% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | 593.88 Million CNY | 99.265% |
| Hubei Guangji Pharmaceutical Co., Ltd. | 935.85 Million CNY | 99.534% |
| Yifan Pharmaceutical Co., Ltd. | 1.99 Billion CNY | 99.781% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 7.55 Billion CNY | 99.942% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | 273.99 Million CNY | 98.407% |
| Boai NKY Medical Holdings Ltd. | 60.4 Million CNY | 92.773% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 62.44 Million CNY | 93.008% |